A5023191265- Ovarian cancer diagnosis and treatment
- Endometrial and Cervical Cancer Treatments
- Immune cells in cancer
- Endometriosis Research and Treatment
- Cancer Immunotherapy and Biomarkers
- Uterine Myomas and Treatments
- Cancer Mechanisms and Therapy
- Cancer Cells and Metastasis
- Ferroptosis and cancer prognosis
- Immune Cell Function and Interaction
- Cytokine Signaling Pathways and Interactions
- Cancer, Stress, Anesthesia, and Immune Response
- Cancer Genomics and Diagnostics
- Inflammation biomarkers and pathways
- Cervical Cancer and HPV Research
- Cancer-related molecular mechanisms research
- RNA modifications and cancer
- Cancer-related gene regulation
- PARP inhibition in cancer therapy
- Sarcoma Diagnosis and Treatment
- Intraperitoneal and Appendiceal Malignancies
- Cancer, Hypoxia, and Metabolism
- MicroRNA in disease regulation
- Cancer Research and Treatments
- Maternal and fetal healthcare
Iwate Medical University
2019-2025
Niigata University
2024
Kyoto University
2014-2023
Duke University
2023
Duke Medical Center
2007-2020
Rigaku (Japan)
2020
Kyoto University Hospital
2012-2016
Kindai University
2015
Duke University Hospital
2009-2011
Kyoto Pharmaceutical University
2011
Purpose Programmed death-1 (PD-1), a coinhibitory immune signal receptor expressed in T cells, binds to PD-1 ligand and regulates antitumor immunity. Nivolumab is an anti–PD-1 antibody that blocks signaling. We assessed the safety activity of nivolumab patients with platinum-resistant ovarian cancer. Patients Methods Twenty cancer were treated intravenous infusion every 2 weeks at dose 1 or 3 mg/kg (constituting two 10-patient cohorts) from October 21, 2011. This phase II trial defined...
PD-L1 (programmed cell death 1 ligand 1) on tumour cells suppresses host immunity through binding to its receptor PD-1 lymphocytes, and promotes peritoneal dissemination in mouse models of ovarian cancer. However, how expression is regulated cancer microenvironment remains unclear. The number CD8-positive lymphocytes was assessed clinical samples. progression under conditions altering IFN-γ signals assessed. stroma very high peritoneally disseminated tumours, strongly correlated the...
Emerging evidence has highlighted the host immune system in modulating patient response to chemotherapy, but mechanism of this modulation remains unclear. The aim study was analyze effect chemotherapy on antitumor immunity tumor microenvironment ovarian cancer. Treatment cancer cell lines with various chemotherapeutic agents resulted upregulated expression MHC class I and programmed death 1 ligand (PD-L1) a NF-κB-dependent manner suppression antigen-specific T-cell function vitro. In mouse...
Abstract IFNγ is a cytokine that plays pivotal role in antitumor host immunity. elicits potent immunity by inducing Th1 polarization, CTL activation, and dendritic cell tumoricidal activity. However, there are significant discrepancies our understanding of the as an cytokine. In certain circumstances, obviously acts to induce tumor progression. treatment has negatively affected patient outcomes some clinical trials, while it favorably other trials. Several mechanisms, including insensitivity...
Snail is a major transcriptional factor that induces epithelial-mesenchymal transition (EMT). In this study, we explore the effect of on tumor immunity. knockdown in mouse ovarian cancer cells suppresses growth immunocompetent mice, associated with an increase CD8+ tumor-infiltrating lymphocytes and decrease myeloid-derived suppressor (MDSCs). reduces expression CXCR2 ligands (CXCL1 CXCL2), chemokines attract MDSCs to via CXCR2. upregulates CXCR through NF-kB pathway, most likely, direct...
Abstract Purpose: High VEGF expression in ovarian cancer is an unfavorable prognostic factor. However, the role of tumor immunity remains unclear. Here, we examined impact on local immunity, including induction myeloid-derived suppressor cells (MDSC), cancer. Experimental Design: High-grade serous (HGSOC) cases were analyzed by gene microarray and IHC for VEGF, CD8, CD33. receptor (VEGFR) 1 VEGFR2 levels MDSCs a mouse model, direct effects VEGF-A MDSC expansion investigated. Gr1+ lymphocyte...
Ovarian cancer often progresses by disseminating to the peritoneal cavity, but how tumor cells evade host immunity during this process is poorly understood. Programmed cell death 1 ligand (PD-L1) known suppress immune system and be expressed in cells. The purpose of study elucidate function PD-L1 dissemination.Ovarian cases were studied microarray immunohistochemistry. expression mouse ovarian line various conditions was assessed flow cytometry. PD-L1-overexpression PD-L1-depleted generated,...
V-domain Ig suppressor of T cell activation (VISTA) is a novel inhibitory immune-checkpoint protein. VISTA expression on tumour cells and the associated regulatory mechanisms remain unclear. We investigated function in cells, evaluated its mechanism activity. was assessed by tissue microarray analysis, immunohistochemical staining western blot. A series vitro assays were used to determine tumour-expressed VISTA. In vivo efficacy syngeneic models. highly expressed human ovarian endometrial...
Tertiary lymphoid structures (TLS) are transient ectopic aggregates whose formation might be caused by chronic inflammation states, such as cancer. However, how TLS induced in the tumor microenvironment (TME) and they affect patient survival not well understood. We investigated distribution relation to infiltrating lymphocytes (TILs) related gene expression high-grade serous ovarian cancer (HGSC) specimens. CXCL13 correlated with presence infiltration of T cells B cells, it was a favorable...
The physiological function of mammalian sperm acrosin has long been believed to be involved in the limited proteolysis oocyte zona pellucida, thus enabling penetrate this extracellular matrix and gain access plasma membrane. Here we show that male mice homozygous for a targeted mutation mouse gene are still fertile spite complete absence protease activity sperm. In vitro fertilization assays verified from mutant pellucida effect fertilization. Therefore, is not essential both penetration
Abstract New approaches beyond PD-1/PD-L1 inhibition are required to target the immunologically diverse tumor microenvironment (TME) in high-grade serous ovarian cancer (HGSOC). In this study, we explored immunosuppressive effect of B7-H3 (CD276) via CCL2–CCR2–M2 macrophage axis and its potential as a therapeutic target. Transcriptome analysis revealed that is highly expressed PD-L1–low, nonimmunoreactive HGSOC tumors, expression negatively correlated with an IFNγ signature, which reflects...
The mechanism of resistance development to anti-VEGF therapy in ovarian cancer is unclear. We focused on the changes tumour immunity post therapy.The frequencies immune cell populations and hypoxic conditions resistant murine tumours clinical samples were examined. expression profiles both proteins genes analysed. impact granulocyte-monocyte colony-stimulating factor (GM-CSF) myeloid-derived suppressor (MDSC) function was evaluated.We found a marked increase reduction number Gr-1 + MDSCs CD8...